ABSTRACT
RESUMEN La meningoencefalitis por el VZV es una patología poco frecuente que se presenta con la reactivación del virus dentro del organismo. OBJETIVO: Describir la presentación clínica de dos pacientes con neuroinfección por VZV posteriormente a infección por SARS-CoV-2. REPORTE DEL CASO: El primer caso corresponde a un hombre de 59 años con antecedente de neumonía moderada por SARS-CoV-2 que después cursó con meningoencefalitis por VZV y, además, desarrolló un síndrome de Ramsay Hunt. El segundo caso es el de una mujer de 37 años con antecedente de infección leve por SARS CoV-2 con un cuadro de cefalea con signos de alarma, en quien se documentó neuroinfección por VZV
ABSTRACT Meningoencephalitis caused by varicella zoster virus is a rare pathology that presents due to the reactivation of the virus in the organism OBJECTIVE: To describe the clinical presentation of two patients with VZV neuroinfection presented after a SARS CoV-2 infection. CASE REPORT: The first case is a 59 year old male with previous moderate SARS CoV-2 infection who presented meningoencephalitis and was diagnosed with Ramsay Hunt's Syndrome. The second case is a 37 year old female with previous SARS CoV-2 infection who presented with an acute onset headache and was documented with VZV neuroinfection.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Encephalitis, Varicella Zoster/virology , COVID-19/complications , Antiviral Agents/therapeutic use , Acyclovir/therapeutic use , Encephalitis, Varicella Zoster/diagnosis , Encephalitis, Varicella Zoster/drug therapyABSTRACT
Resumen Introducción: el SARS-COV-2 es un nuevo virus que ha traído nuevos retos a los sistemas de salud a nivel mundial y que ha generado controversia en la continuidad en el uso de bloqueadores del receptor de angiotensina por su correlación fisiopatológica con el SARS-COV-2. Objetivo: presentar la evidencia disponible y las actuales recomendaciones sobre el uso de receptores de la enzima convertidora de angiotensina en el tratamiento para COVID-19. Materiales y métodos: se realizó una búsqueda narrativa en la base de datos PubMed sobre artículos que hablaran acerca del receptor de la enzima convertidora de angiotensina asociado a la pandemia actual por COVID-19. El límite de publicación fue el 13 de abril de 2020 y se incluyeron artículos en todos los idiomas. Resultados: se encontraron 14 artículos con contenido científico significativo para el objetivo de la presente revisión. Conclusión: la fisiopatología del SARS-COV-2 aún es desconocida, así como la efectividad de diferentes fármacos de uso cotidiano para su tratamiento. Dentro de los diferentes medicamentos que se han probado para detener el contagio y sus efectos están aquellos con efecto sobre el receptor de la enzima convertidora de angiotensina.
Abstract Introduction: As a new disease, SARS-COV-2 is a new challenge for healthcare system worldwide, with physiopathology under study and controversy about Angiotensin Converting Enzyme Blockers use because of It's physiopatological correlation with SARS-Cov-2. Objetive: Search for novel literature and recent recomendations about use of Angiotensin Converting Enzyme Blockers during Covid-19 illness. Materials and Methods: We look for narrative literature at PubMed Database for articles about Angiotensin Converting Enzyme and Covid-19 pandemic. Searching limit was April 13 of2.020, we included all languages. Results. We included 14 articles with significative scientific content for review objetive. Conclusion: SARS-Cov-2 Physiopatology is still unclear, also, pharmacology effectiveness in it's treatment. One of these pharmacology groups are the Angiotensin Converting Enzyme Blockers with uncertainty about it's safety during COVID-19 illness.
Subject(s)
Humans , Male , Female , Peptidyl-Dipeptidase A , COVID-19 , Respiratory Distress Syndrome, Newborn , Receptors, Angiotensin , Colombia , Severe acute respiratory syndrome-related coronavirusABSTRACT
Abstract Introduction: Catheter-associated urinary tract infections (CAUTI) account for up to 30% of hospital -acquired infections. In this regard, several studies have reported the use of non-pharmacological interventions during urinary catheter insertion aimed at reducing the occurrence rate of CAUTI. Objective: To assess the safety and effectiveness of non-pharmacological interventions during urinary catheter insertion aimed at reducing the risk of contracting infections in non-immunocompromised adults. Materials and methods: A literature review was conducted in the MEDLINE, Embase, and LILACS databases. Only randomized clinical trials comparing the use of non-pharmacological interventions to placebos, pharmacological interventions, or no intervention during catheter insertion were included. Results: Eight studies were retrieved (8 718 participants). Based on the evidence found in the review (low-quality and very low-quality evidence according to the GRADE system), using non-pharmacological interventions reduces the frequency of asymptomatic bacteriuria episodes (RR 0.67, 95%CI 0.48-0.94; 7 studies) or mild adverse events (RR 0.84, 95%CI 0.74-0.96; 2 studies), but does not reduce the occurrence rate of symptomatic urinary tract infections (RR 0.90, 95%CI 0.61-1.35; 4 studies) or improves quality-of-life scores (MD -0.01 EQ-5D scale; 95%CI (-0.03)-(0.01), 1 study). Conclusion: The use of non-pharmacological interventions during urinary catheter insertion does not pose any risk at all. Instead, it could help reduce the occurrence rate of infections associated with this procedure, such as asymptomatic bacteriuria and mild adverse events. However, there is very little evidence (in fact, low and very low-quality evidence) to make conclusions on the effectiveness of these interventions.
Resumen Introducción. La infección asociada al catéter urinario es responsable de hasta un 30% de las infecciones nosocomiales. Al respecto, se ha descrito el uso de intervenciones no farmacológicas durante la inserción del catéter urinario para reducir la frecuencia de infecciones asociadas. Objetivo. Evaluar la seguridad y la efectividad de intervenciones no farmacológicas durante la inserción del catéter urinario diseñadas para reducir el riesgo de infección en adultos inmunocompetentes. Materiales y métodos. Se realizó una búsqueda en las bases de datos MEDLINE, Embase y LILACS. Se incluyeron ensayos clínicos aleatorizados que compararan el uso de intervenciones no farmacológicas con el uso de placebos, el uso de intervenciones farmacológicas o la ausencia de intervención durante la inserción del catéter. Resultados. Se encontraron ocho estudios (8 718 participantes). Con base en la evidencia encontrada (baja y muy baja calidad según la clasificación del sistema GRADE), el uso de intervenciones no farmacológica reduce la frecuencia de bacteriuria asintomática (RR 0.67; IC95%: 0.48-0.94; 7 estudios) o de eventos adversos menores (RR 0.84, IC95%: 0.74-0.96; 2 estudios), pero no disminuye la tasa de infecciones sintomáticas del tracto urinario (RR 0.90; IC95%: 0.61 a 1.35; 4 estudios), ni mejora las puntuaciones de calidad de vida (escala MD -0.01 EQ-5D, IC95%: (-0.03)-(0.01), 1 estudio). Conclusión. El uso de intervenciones no farmacológicas durante la inserción del catéter urinario no supone riesgo alguno y sí podría ayudar a disminuir la frecuencia infecciones asociadas a este procedimiento, tales como la bacteriuria asintomática y eventos adversos menores; sin embargo, hay poca evidencia, y de baja o muy baja calidad, para llegar a conclusiones sobre su efectividad.
ABSTRACT
Objective@#To evaluate treatment experience for mesh infection after inguinal hernia repair.@*Methods@#392 cases underwent surgery for mesh infection after inguinal hernia repair in Beijing Chaoyang Hospital from Jan 2007 to Jun 2018. For mesh infection after open inguinal hernia repair, infected mesh and tissue were removed by open operation, while laparoscopic operation was adopted for mesh infection after laparoscopic inguinal hernia repair. Time of infection, type of bacteria, and hernia recurrence were evaluated.@*Results@#369 cases suffered mesh infection after open inguinal hernia repair and 23 cases were after laparoscopic inguinal hernia repair. 61 cases suffered mesh infection within 3 months, 258 cases were from 3 months to 1 year and 73 cases were after one year. During follow up of 6 to 36 months after operation, 29 cases suffered hernia recurrence in 24 to 34 months after removal of mesh. Bacterial culture were positive in 193 cases, including 126 cases of staphylococcus aureus, 18 cases of escherichia coli and 15 cases of pseudomonas aeruginosa.@*Conclusion@#Individualized treatment policy based on original mesh placement is safe and effective for mesh infection after inguinal hemiorrhaphy.
ABSTRACT
Objective To evaluate treatment experience for mesh infection after inguinal hernia repair.Methods 392 cases underwent surgery for mesh infection after inguinal hernia repair in Beijing Chaoyang Hospital from Jan 2007 to Jun 2018.For mesh infection after open inguinal hernia repair,infected mesh and tissue were removed by open operation,while laparoscopic operation was adopted for mesh infection after laparoscopic inguinal hernia repair.Time of infection,type of bacteria,and hernia recurrence were evaluated.Results 369 cases suffered mesh infection after open inguinal hernia repair and 23 cases were after laparoscopic inguinal hernia repair.61 cases suffered mesh infection within 3 months,258 cases were from 3 months to 1 year and 73 cases were after one year.During follow up of 6 to 36 months after operation,29 cases suffered hernia recurrence in 24 to 34 months after removal of mesh.Bacterial culture were positive in 193 cases,including 126 cases of staphylococcus aureus,18 cases of escherichia coli and 15 cases of pseudomonas aeruginosa.Conclusion Individualized treatment policy based on original mesh placement is safe and effective for mesh infection after inguinal hemiorrhaphy.